MedPath

A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®

Completed
Conditions
Asthma
Registration Number
NCT00532922
Lead Sponsor
AstraZeneca
Brief Summary

The purpose of this study is to investigate real practices of treatment with Symbicort Turbuhaler for 3 months in asthma and patient compliance.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
310
Inclusion Criteria
  1. Provision of informed consent
  2. Asthmatics who has been prescribed Symbicort according to physician's judgement
  3. Usage of Symbicort should follow local prescribing information
Read More
Exclusion Criteria
  1. Not being involved in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
  2. No previous enrolment in the present study
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Research Site

🇨🇳

Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath